Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07077486 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

StatusRecruiting
PhasePhase 4
Started2025-08-25
View on ClinicalTrials.gov ↗

Amendment history

2026-01-25
Enrolling by Invitation→Recruiting Study Status, Sponsor/Collaborators, Contacts/Locations v1
Trial statusEnrolling by Invitation→Recruiting
Primary completion date2025-12-25→2026-10-25
Completion date2025-12-25→2027-03-25
Start dateestimated 2025-07-25→confirmed 2025-08-25
Study sitesdetails revised at 1 of 1 site
Collaborators2 to 4 entries
Rongchang Biopharmaceutical Johns Hopkins Bloomberg School of Public Health
2025-07-21
Original filing
Tongji Hospital
197 trials monitored
See 2 trials at risk
Lupus (SLE)
648 trials monitored
See 25 trials at risk
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.
Trial Details
NCT Number NCT07077486
Lead Sponsor Tongji Hospital
Collaborators: Wuhan Central Hospital, Wuhan Hospital of Traditional Chinese Medicine, Rongchang Biopharmaceutical, Johns Hopkins Bloomberg School of Public Health
Conditions Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
Enrollment 100 participants
Start Date 2025-08-25
Primary Completion 2026-10-25 (estimated)
Study Completion 2027-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-01-27